Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours.
about
The protease inhibitor bikunin, a novel anti-metastatic agentEnzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness.Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision MedicineInhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinaseDrug development against metastasis-related genes and their pathways: A rationale for cancer therapyProteomic identification of LASP-1 down-regulation after RNAi urokinase silencing in human hepatocellular carcinoma cellsAssessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future ProspectsThe Oral Serine Protease Inhibitor WX-671 - First Experience in Patients with Advanced Head and Neck Carcinoma.Experience in Phase I Trials and an Upcoming Phase II Study with uPA Inhibitors in Metastatic Breast Cancer.CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review.Angiogenesis in non-small cell lung cancer. A new target for therapy.2-Amidino analogs of glycine-amiloride conjugates: inhibitors of urokinase-type plasminogen activator.Angiogenesis in melanoma.Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancerTumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms.Clinical Response of Metastatic Breast Cancer to Multi-targeted Therapeutic Approach: A Single Case Report.Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.Transforming growth factor-beta1-dependent urokinase up-regulation and promotion of invasion are involved in Src-MAPK-dependent signaling in human ovarian cancer cells.Genetic down-regulation of phosphoinositide 3-kinase by bikunin correlates with suppression of invasion and metastasis in human ovarian cancer HRA cells.Inhibition of intraperitoneal tumor growth of human ovarian cancer cells by bi- and trifunctional inhibitors of tumor-associated proteolytic systems.Novel bi- and trifunctional inhibitors of tumor-associated proteolytic systems.High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread.Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.Recanalization and remodeling of the great saphenous vein caused by the large melanoma's cutaneous metastasis.
P2860
Q24305858-6616BC3A-8771-481E-9E1A-18DAF32F4B1AQ24533487-EA9D2CBA-3379-4E81-830B-0A507776462DQ28067626-443945BB-A0FB-4225-A914-0A84148C8E77Q28241119-B02A8B64-361C-4A94-B143-E12069FDA3E3Q29010479-BE7D36B9-17AC-472F-8BA3-27285408BCA2Q30157380-1E3C0E2D-B503-46E1-B3FC-8994F35A82BAQ34095769-6AA65C9D-E1AE-4653-A366-C4813794BFCFQ34095782-3ED12DF7-900A-4BDC-A71B-B003149C1E0DQ34095789-676685D8-5BB2-4680-9A71-34C7031EC727Q35606333-BB5FB9DD-0876-4EDF-9EA3-83FFA562885DQ35627784-91870200-E7F1-4A5B-9626-48AC4DBA70C3Q35898448-C6FCF7C2-D035-4C5A-98D8-801D523FBB32Q36626892-07125C9B-86EC-4742-90C7-80883992DA28Q36663677-88833961-7127-4B45-BC2B-677FCD2D1D9FQ36761523-06A6A6AC-DEDA-452C-892E-4BFFF20B0CD6Q37129903-37590DD5-81D2-459D-B9AA-016B5880C9D1Q37809871-E2AA4514-D62F-408C-B0B5-5966031D5E31Q37899888-E470D3BB-D35C-43D5-8C59-FD87C915E899Q40607325-081C733B-499B-442D-A5E0-D72CC900C57EQ40620238-B5BBE080-8FC4-45C1-98B7-8D77BADB15A5Q40637635-062D2B35-AC37-456C-A400-8A5766E58DACQ40637642-F27A0649-3FF5-461B-8D0E-84326701864BQ44151258-CAF5B11B-DEB7-47F3-913D-E8CA9FE843BDQ54960825-8B21A0F4-4BFC-4278-8855-DC62B6A6FFDAQ55008113-50950528-E193-42D2-8CF1-C09C301CD666
P2860
Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Interference with the urokinas ...... apy concept for solid tumours.
@ast
Interference with the urokinas ...... apy concept for solid tumours.
@en
Interference with the urokinas ...... apy concept for solid tumours.
@nl
type
label
Interference with the urokinas ...... apy concept for solid tumours.
@ast
Interference with the urokinas ...... apy concept for solid tumours.
@en
Interference with the urokinas ...... apy concept for solid tumours.
@nl
prefLabel
Interference with the urokinas ...... apy concept for solid tumours.
@ast
Interference with the urokinas ...... apy concept for solid tumours.
@en
Interference with the urokinas ...... apy concept for solid tumours.
@nl
P2093
P2860
P356
P1476
Interference with the urokinas ...... apy concept for solid tumours.
@en
P2093
P2860
P304
P356
10.1517/14712598.1.4.683
P407
P577
2001-07-01T00:00:00Z